Harvard Bioscience (HBIO) Invested Capital (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Invested Capital data on file, last reported at $10.0 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $10.0 million, down 80.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 million (down 80.22% YoY), and the FY2025 annual result was $13.7 million, down 86.31% from the prior year.
• Invested Capital eased to $10.0 million in Q1 2026 per HBIO's latest filing, from $13.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $126.0 million in Q2 2022 and troughed at $10.0 million in Q1 2026.
• A 5-year average of $90.2 million and a median of $104.4 million in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital rose 3.86% in 2022, then tumbled 86.31% in 2025.
• A 5-year view of Invested Capital shows it stood at $119.0 million in 2022, then dropped by 7.9% to $109.6 million in 2023, then decreased by 8.52% to $100.3 million in 2024, then plunged by 86.31% to $13.7 million in 2025, then slipped by 26.85% to $10.0 million in 2026.
• Business Quant data shows HBIO's Invested Capital at $10.0 million in Q1 2026, $13.7 million in Q4 2025, and $48.0 million in Q3 2025.